Opinion|Videos|September 18, 2024
Fruquintinib in mCRC: Key Insights From FRESCO-2
Medical experts highlight key data from the FRESCO-2 trial on fruquintinib for previously treated metastatic colorectal cancer, focusing on study population, efficacy, and safety, and discuss real-world experience with fruquintinib compared with trial outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- New to our arsenal of drugs is fruquintinib, an additional option for previously treated metastatic colorectal cancer based on the FRESCO-2 data. What are some highlights of this data in terms of the study population, efficacy, and safety?
- Include in this discussion that all patients previously received regorafenib or FTD/TPI.
- What has been your experience using fruquintinib in practice, and how do patient outcomes compare with what was seen in FRESCO-2?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
CMS Final Rule Ends Federal Medicaid, CHIP Funding for Youth Gender-Affirming Care
2
Trump Childhood Vaccine Order: What It Means for Parents and Payers
3
CAR T, Bispecifics Reshape Relapsed Lymphoma Care: Madhav Seshadri, MD
4
OCTOPUS Trial Aims to Speed Access to Rare Sarcoma Drugs
5